How to Validate miRNA Targeting: Western Blot Analysis

MicroRNAs (miRNAs) are non-coding RNA molecules, usually 19-22 nucleotides long, that modulate gene expression by binding to specific mRNA targets. This interaction involves both the translation process and the stability of the mRNAs, thereby affecting gene expression after transcription. Their regulatory activity is carried out by binding to complementary sequences on target mRNAs, usually at their 3' UTR level, and resulting in their degradation or inhibition of translation. Given their ability to modulate the expression of targeted molecules, miRNAs can act either as oncogenes or tumor suppressor genes in cancer cells. Aberrant miRNA expression can lead to irregular gene expression, contributing to cancer development. Changes in miRNA expression profiles have been documented across multiple cancer types and are linked to clinical factors, such as tumor progression, metastasis, and patient survival rates. Certain miRNAs have potential as diagnostic biomarkers for early cancer detection and can serve as prognostic markers to predict patient outcomes and response to treatments. This chapter outlines the experimental procedures for validating microRNA targets through Western blotting. Western blotting, a "gold-standard" technique for protein analysis, offers a reliable approach for validating the impact of miRNAs on their target genes by assessing protein expression levels [1]. This validation is essential for understanding the roles miRNAs play in health and disease.